GlaxoSmithKline Lowered to “Neutral” at Citigroup Inc. (GSK)
GlaxoSmithKline (NYSE:GSK) was downgraded by Citigroup Inc. from a “buy” rating to a “neutral” rating in a research note issued on Tuesday, StockRatingsNetwork reports.
A number of other analysts have also recently weighed in on GSK. Analysts at Cowen and Company upgraded shares of GlaxoSmithKline (NYSE:GSK) from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, August 21st. Separately, analysts at Morgan Stanley downgraded shares of GlaxoSmithKline (NYSE:GSK) from an “equal weight” rating to an “underweight” rating in a research note to investors on Thursday, August 15th. Finally, analysts at JPMorgan Chase & Co. upgraded shares of GlaxoSmithKline (NYSE:GSK) from an “underweight” rating to a “neutral” rating in a research note to investors on Wednesday, August 14th.
Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $87.60.
Shares of GlaxoSmithKline (NYSE:GSK) opened at 50.20 on Tuesday. GlaxoSmithKline has a 52 week low of $41.68 and a 52 week high of $54.00. The stock’s 50-day moving average is $51.62 and its 200-day moving average is $50.0. The company has a market cap of $121.6 billion and a price-to-earnings ratio of 19.20.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 24th. The company reported $0.26 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.26. The company had revenue of $6.62 billion for the quarter. GlaxoSmithKline’s revenue was up 5.5% compared to the same quarter last year. Analysts expect that GlaxoSmithKline will post $3.57 EPS for the current fiscal year.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.